StudyFinder

Protocol M23-716: A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata

Status: Recruiting

Description:

This study will assess how effective and safe the use of the medication named Upadacitinib is for the treatment of signs and symptoms of severe hair loss in adults.

I'm interested

Sex: Male or Female

This study is NOT accepting healthy volunteers

Inclusion Criteria:

• 12-63 years of age
• have more than 50% hair loss

Exclusion Criteria:

• pregnancy

Conditions:

Dermatology (Skin, Hair & Nails)

Keywords:

Alopecia Areata

Study Contact: Dermatology Study - dermresearch@umn.edu

Principal Investigator: Maria Hordinsky

IRB Number: STUDY00021415

Back

Protocol M23-716: A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata

Email this study information to me

Contact the study team